Company: BDRX
Filing Date: 2025-08-18
Form Type: 424B3
Source: 0001214659-25-012378
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-08-18
Form: 424B3
Chunk 2
---
 as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: August 18, 2025 |     | Biodexa Pharmaceuticals PLC                      
 (Registrant)                                     
 /s/ Stephen Stamp                                |
|:----------------------|:----|:-------------------------------------------------|
|                       |     | Stephen Stamp                                    |
|                       |     | Chief Executive Officer, Chief Financial Officer |

EXHIBIT 99.1

<div align='center'>Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)</div>

August 18, 2025

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial

in Familial Adenomatous Polyposis (FAP)

Opportunity to be First Mover in $7.3Bn Addressable Market

Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the enrolment of the first two patients by the Pan American Center for Oncology Trials in San Juan, Puerto Rico into its pivotal Phase 3 Serenta trial of eRapa in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. The only current treatment option is sequential resection of the gastrointestinal tract.

Commenting, Stephen Stamp CEO and CFO of Biodexa said “Enrolling the first patients in our pivotal Phase 3 study in FAP is a seminal event for our company, our collaborator Emtora Biosciences and our CRO, LumaBridge. As the only drug candidate for FAP in Phase 3, our combined